医学
中医药
冲程(发动机)
PI3K/AKT/mTOR通路
信号转导
药理学
传统医学
MAPK/ERK通路
生物信息学
蛋白激酶B
替代医学
生物
病理
机械工程
生物化学
工程类
作者
Xinghua Li,Feng-Ting Yin,Xiaohang Zhou,Aihua Zhang,Hui Sun,Yan Ge,Xijun Wang
出处
期刊:Molecules
[MDPI AG]
日期:2022-05-12
卷期号:27 (10): 3099-3099
被引量:18
标识
DOI:10.3390/molecules27103099
摘要
Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage, r-tPA is currently used in less than 5% of stroke patients. Natural compounds have been widely used in the treatment of IS in China and have a wide range of therapeutic effects on IS by regulating multiple targets and signaling pathways. The keywords "ischemia stroke, traditional Chinese Medicine, Chinese herbal medicine, natural compounds" were used to search the relevant literature in PubMed and other databases over the past five years. The results showed that JAK/STAT, NF-κB, MAPK, Notch, Nrf2, and PI3K/Akt are the key pathways, and SIRT1, MMP9, TLR4, HIF-α are the key targets for the natural compounds from traditional Chinese medicine in treating IS. This study aims to update and summarize the signaling pathways and targets of natural compounds in the treatment of IS, and provide a base of information for the future development of effective treatments for IS.
科研通智能强力驱动
Strongly Powered by AbleSci AI